
	Where results make sense

Topic: NIAID

Related Topics

New Jersey State Highway 208

Minguo

Scottish Deerhound

Presbyterian Church in the United States

TLI

Winfield, Indiana

Nerve agent

Drew, Maine

Hobro

Amhara

Robots in literature

British Police

Reform Judaism

Hundertwasserhaus

Mentat

In the News (Mon 7 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	NIAID Initiates Trial of Experimental Avian Flu Vaccine, March 23, 2005 Press Release - National Institutes of Health ...
		NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services.
		NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism.
		NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
	www.nih.gov /news/pr/mar2005/niaid-23.htm (502 words)

	Report on the Rare Diseases and Conditions Research Activities of the National Institutes of Health FY 2001 - Table of ... (Site not responding. Last check: 2007-11-01)
		NIAID intramural investigators sequenced and characterized the genome of GAS strain MGAS8232 (serotype M18) isolated from a patient with acute rheumatic fever and compared it to the genome of strain SF370 (serotype M1 strain).
		NIAID intramural investigators and their international collaborators are conducting a clinical study of Peruvian patients with inactive cysticercosis (disease caused by encystment of tapeworm larvae).
		NIAID researchers are conducting a clinical study of hyperimmunoglobulin E syndrome patients and their relatives to better understand the medical problems associated with this disease, identify and treat complications, and identify responsible genes.
	rarediseases.info.nih.gov /html/reports/fy2001/niaid.html (8343 words)

	NIAID Fact Sheet
		Recent studies by NIAID intramural and extramural researchers have identified multiple coreceptors for different types of HIV strains; these coreceptors are promising targets for new anti-HIV drugs.
		NIAID researchers have shown that even early in disease, HIV actively replicates within the lymph nodes and related organs, where large amounts of virus become trapped in networks of specialized cells with long, tentacle-like extensions.
		The NIAID HIV/AIDS Research Agenda and fact sheets on NIAID HIV/AIDS vaccine research, clinical trials for AIDS therapies and vaccines, and AIDS-related opportunistic infections are available from the NIAID Office of Communications.
	www.albany.edu /sph/AIDS/howhiv.html (5114 words)

	Malaria, NIAID Fact Sheet: NIAID - WrongDiagnosis.com
		NIAID is one of 17 institutes of the National Institutes of Health (NIH), the federal focal point for biomedical research.
		NIAID investigators are planning the first human trial of a vaccine designed specifically to block the transmission of malaria parasites from infected people.
		So far, NIAID researchers have identified five molecules in addition to Pfs25 to try in such vaccines, and they have cloned the genes for four, which can be used in other candidate vaccines.
	www.wrongdiagnosis.com /artic/malaria_niaid_fact_sheet_niaid.htm (1789 words)

	The Body: About National Institute of Allergy and Infectious Diseases (NIAID)
		NIAID is composed of four extramural divisions: the Division of AIDS, the Division of Allergy, Immunology and Transplantation, the Division of Microbiology and Infectious Diseases, and the Division of Extramural Activities.
		NIAID has established a network of asthma, allergic, and immunologic diseases research centers to transfer results from fundamental studies in immunology and clinical studies of allergy to clinical practice.
		NIAID is participating in the first NIH cooperative clinical trial in kidney transplantation, designed to translate developments in basic research into new therapies to prevent graft rejection.
	www.thebody.com /niaid/niaid.html (893 words)

	AEGiS-NIAID: HIV Infection and AIDS
		NIAID and its grantees are actively studying the new clinical syndrome of disease among persons on long term-therapy.
		NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and Human Services.
		NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.
	www.aegis.com /topics/basics/hivandaids.html (6133 words)

	NIH Guide: TROPICAL DISEASE RESEARCH UNITS
		As a focus of this strategic plan, the NIAID has identified a number of priority organisms, including several food and water borne protozoan pathogens (http://www.niaid.nih.gov/biodefense/bandc_priority.htm).
		Current parasitology research supported by the DMID, NIAID, is largely conducted under investigator initiated research project grants focusing on the molecular and cellular biology, immunology, and biochemistry of the medically important protozoa and helminths as well as on the biology of invertebrate vectors.
		Although the financial plans of NIAID provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.
	grants1.nih.gov /grants/guide/rfa-files/RFA-AI-03-018.html (3503 words)

	NIAID And VaxGen, Inc. Collaborate On AIDS vaccine Studies
		NIAID is also studying other vaccine designs aimed at stimulating different components of the immune system.
		These activities are part of NIAID's ongoing efforts to determine systematically the effects of immunization and the potential for different approaches to prevent HIV disease.
		NIAID, in collaboration with other companies, is exploring other strategies, including a combination vaccine that attempts to induce both cytotoxic T cells and antibodies.
	www.hivpositive.com /f-Topics/AIDS-Topics/AIDSvaccine.html (1220 words)

	The Body: HIV Infection in Minority Populations
		NIAID supports scientific research at universities, medical schools, hospitals, and research institutions, both in the United States and internationally.
		NIAID is currently implementing an HIV Vaccine Communications Campaign (HVCC), which is aimed at increasing awareness of and support for HIV vaccine research, especially in at-risk populations.
		NIAID receives input and guidance for developing appropriate and culturally sensitive messages from its HIV Vaccine Communications Steering Group, which consists of representatives from community groups, other government agencies, pharmaceutical companies, and HIV vaccine advocacy groups.
	www.thebody.com /niaid/minor.html (1606 words)

	NIAID Glossary of Funding and Policy Terms and Acronyms: E-H -- NIAID Research Funding (Site not responding. Last check: 2007-11-01)
		NIAID management committee comprising staff from the NIAID Office of the Director, division directors, and other managers.
		NIAID staff member who ensures that both the granting agency and grantees meet all requirements of laws, regulations, and policies.
		NIAID staff member who is the focal point for all business and policy activities associated with the negotiation, award, and administration of a grant or cooperative agreement, and who interprets and applies grants policies.
	www.vrc.nih.gov /ncn/glossary/default3.htm (2709 words)

	Clinical Alert: International HIV/AIDS Trial Finds Continuous Antiretroviral Therapy Superior to Episodic Therapy
		NIAID made the decision to halt enrollment in collaboration with the study's Executive Committee and following a recommendation received from an independent Data and Safety Monitoring Board (DSMB).
		An earlier NIAID news release describing the initiation of the SMART trial can be viewed at http://www3.niaid.nih.gov/news/newsreleases/2002/smart.htm.
		It was hypothesized that the DC strategy would result in lower rates of disease progression and serious toxicities as compared to the VS strategy in the planned follow-up period ranging from 6 to 9 years.
	www.nlm.nih.gov /databases/alerts/aids_smart.html (2301 words)

	PAR-02-018: RESEARCH SCHOLAR DEVELOPMENT AWARD
		TERMS AND CONDITIONS OF THE AWARD When clinical studies or trials are a component of the research proposed, NIAID policy requires that studies be monitored commensurate with the degree of potential risk to study subjects and the complexity of the study.
		NIAID policy was announced in the NIH Guide on February 24, 2000 and is available at: http://grants.nih.gov/grants/guide/notice-files/NOT-AI-00-003.html.
		The adequacy of the proposed protection for humans, animals, or the environment to the extent they may be adversely affected by the activities proposed in the application.
	grants.nih.gov /grants/guide/pa-files/PAR-02-018.html (3599 words)

	CIDRAP >> NIAID funds 11 new biodefense labs
		The sites were chosen on the basis of "the scientific and technical merit of the application as assessed by peer review and on the applicant's ability to contribute to the overall NIAID research agenda," the news release stated.
		The NIAID said the 11 new labs will "complement and support" the research conducted at the NIAID's recently designated Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases.
		According to a NIAID fact sheet, BSL-4 labs can handle pathogens that pose a high risk of causing a life-threatening disease for which there is no vaccine or treatment, such as Ebola virus.
	www.cidrap.umn.edu /cidrap/content/bt/bioprep/news/oct0103labs.html (709 words)

	NIAID Announces Senior Management Appointments
		Prior to his appointment at NIAID, Dr. Auchincloss was Professor of Surgery at Harvard Medical School where he earned an international reputation in the field of organ transplantation.
		For more than 17 years, he operated a laboratory in transplantation immunology at Massachusetts General Hospital in Boston with multiple research interests, including the mechanisms and control of tissue graft rejection, the mechanisms of transplantation tolerance induction, the use of pancreas and islet transplantation for the treatment of diabetes, and the prevention of recurrent autoimmunity.
		Folkers came to NIAID in 1991 after being employed in various writing and communications positions in the Boston area.
	www.nieuwsbank.nl /en/2006/02/06/r023.htm (993 words)

	Biodefense: A plague of researchers \| thebulletin.org
		On February 11, a scientist at Rocky Mountain Laboratories, a NIAID research facility in Hamilton, Montana, was exposed to the bacterium that causes Q fever while working in a Biosafety Level 3 (BSL-3) lab.
		According to NIAID, early detection of Q fever infection is difficult, and the Centers for Disease Control and Prevention says that Q fever "probably presents the greatest risk of laboratory infection" among its family of diseases.
		Hammond believes the way to solve this confusion is for NIAID to publicize both the dollar value of the grants it hands out as well as a description of the research.
	www.thebulletin.org /article.php?art_ofn=mj05schwellenbach (1241 words)

	NIAID: Recommendations for a Research Agenda
		On December 14, 1998, the NIAID hosted a groundbreaking workshop bringing together top researchers from all over the United States and the world to discuss a potential infectious etiology of Crohn's disease and to devise new research approaches to address this critical concern.
		All shared their personal and scientific experiences and the outcome was excellent, resulting in a document that has as its underpinning the human affliction and stresses the need to define the potential infectious etiology, characterize the host immune and inflammatory responses and conduct crucial epidemiological and familial genetic research.
		The NIAID is extremely well placed to execute this research, being the force responsible for the creation of many of the groundbreaking molecular techniques in use in infectious disease research around the world today.
	www.crohns.org /research/niaid.htm (2838 words)

	Scientists Unveil Piece of HIV Protein that May Be Key to AIDS Vaccine Development, February 14, 2007 News Release - ...
		His collaborators included other scientists from NIAID and the National Cancer Institute, NIH, as well as investigators from the Dana-Farber Cancer Institute, Boston, and The Scripps Research Institute in La Jolla, CA.
		NIAID is a component of the National Institutes of Health.
		NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.
	www.nih.gov /news/pr/feb2007/niaid-14.htm (915 words)

	NIAID launches influenza genome sequencing project
		The sequencing effort, to be conducted in part by the NIAID Microbial Sequencing Center at TIGR, will reveal complete genetic blueprints of thousands of known human and avian influenza viruses.
		NIAID will rapidly make this sequence information publicly available through GenBank®, an international, searchable online database funded by NIH, and the NIAID Bioinformatics Resource Center, a Web-accessible collection of genetic sequence information accompanied by data analysis tools.
		Giovanni notes that NIAID is working with collaborators who have well-defined collections of human and avian influenza viruses.
	www.eurekalert.org /pub_releases/2004-11/nioa-nli111504.php (635 words)

	ScienceDaily: NIAID Initiates Trial Of Experimental Avian Flu Vaccine
		NIAID Announces Contracts To Develop Vaccine Against H5N1 Avian Influenza (June 1, 2004) -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded two contracts to support the production and clinical testing of an...
		NIAID Launches Malaria Vaccine Trial In Africa (September 11, 2003) -- The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, has reached a milestone in its efforts to support accelerated development of malaria...
		NIAID Begins Enrolling Volunteers For Novel HIV Vaccine Study (January 28, 2005) -- A large clinical trial of a novel HIV vaccine has begun enrolling volunteers at sites in North America, South America, the Caribbean and Australia.
	www.sciencedaily.com /releases/2005/03/050325100848.htm (1715 words)

	Science & Medicine \| NIAID Awards $81 Million in Grants to Four Biotech Companies for HIV Vaccine Research, Development ...
		The grants are part of NIAID's HIV Vaccine Design and Development Teams program, which is a public-private partnership aimed at accelerating HIV vaccine development, according to a NIAID release.
		NIAID awarded the five-year grants to Research Triangle Park, N.C.-based AlphaVax; San Diego, Calif.-based Epimmune; Columbia, Md.-based Novavax; and Progenics Pharmaceuticals of Tarrytown, N.Y.,
		NIAID Director Dr. Anthony Fauci said, "A safe and effective HIV vaccine is critical to the control of HIV globally.
	www.kaisernetwork.org /daily_reports/rep_index.cfm?hint=1&DR_ID=20094 (428 words)

	U.S. Health Agency To Speed Flu Vaccine Development - US Department of State
		HHS Secretary Mike Leavitt today announced that the National Institute of Allergy and Infectious Diseases (NIAID) and MedImmune Inc. have signed a cooperative research and development agreement for the development of vaccines against avian influenza viruses that have the potential to cause pandemics.
		NIAID and MedImmune will develop at least one vaccine for each of the 16 variations of a key influenza surface protein known as hemagglutinin (represented by the letter "H" in the names of influenza strains, such as H5N1). NIAID and MedImmune will develop vaccines for the highest priority hemagglutinin subtypes first.
		Under the agreement, NIAID and MedImmune will use methods such as reverse genetics and classical reassortment to place hemagglutinin genes with pandemic potential into an attenuated human flu virus.
	usinfo.state.gov /gi/Archive/2005/Sep/29-562277.html?... (1130 words)

	ScienceDaily: NIAID Launches First Phase II Trial Of A 'Global' HIV/AIDS Vaccine
		The experimental vaccine was developed by scientists at NIAID's Daleand Betty Bumpers Vaccine Research Center (VRC) and is being studied inthe HIV Vaccine Trials Network (HVTN), a clinical researchcollaboration funded by NIAID's Division of AIDS (DAIDS).
		NIAID supports basic andapplied research to prevent, diagnose and treat infectious diseasessuch as HIV/AIDS and other sexually transmitted infections, influenza,tuberculosis, malaria and illness from potential agents ofbioterrorism.
		NIAID Initiates Trial Of Experimental Avian Flu Vaccine (March 25, 2005) -- Fast-track recruitment has begun for a trial to investigate the safety of a vaccine against H5N1 avian influenza, the National Institute of Allergy and Infectious Diseases (NIAID), part of the...
	www.sciencedaily.com /releases/2005/10/051018070342.htm (2163 words)

	NIAID Announces Leadership For Newly Restructured HIV/AIDS Clinical Trials Networks
		The National Institute of Allergy and Infectious Diseases (NIAID) today announced the clinical investigators and institutions that will lead NIAID's newly restructured HIV/AIDS clinical trials networks in the search for safe and effective treatments and prevention strategies, including HIV vaccines.
		NIAID, part of the National Institutes of Health (NIH), supports the world's largest portfolio of clinical HIV/AIDS research.
		Because the leadership awards represent the first of two sets of awards for the clinical trials networks, NIAID is issuing these awards with provisional funding.
	www.medicalnewstoday.com /medicalnews.php?newsid=46343&nfid=rssfeeds (854 words)

	WebWire® \| Researchers Discover New Disease-Causing Bacterium in Patients with Rare Immune Disorder
		Since the initial acceptance of this study for publication, NIAID researchers have isolated Granulobacter bethesdensis bacteria from two additional patients with CGD who were experiencing clinical symptoms similar to those of the initial CGD patient.
		Other infections were never successfully treated,” says Steven M. Holland, M.D., chief of NIAID’s Laboratory of Clinical Infectious Diseases.
		A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease.
	www.webwire.com /ViewPressRel.asp?aId=12670 (911 words)

	NIAID Initiates Trial of Experimental Avian Flu Vaccine
		NIAID > News and Events > News Releases > 2005
		Related News Release: NIAID Announces Contracts to Develop Vaccine Against H5N1 Avian Influenza
		NIAID is a component of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services.
	www3.niaid.nih.gov /news/newsreleases/2005/avianfluvax.htm (542 words)

Try your search on: Qwika (all wikis)